Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Quick Listen: Scrip's Five Must-Know Things

Executive Summary

In this week's podcast edition of Five Must-Know Things: Axsome gets broad label for new depression drug; Argenx CEO on Vyvgart’s success; Chinese firms delist from US; solid results for Novo Nordisk’s new diabetes combo; and women leaders herald change at foreign firms in India.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 26 August 2022, including: Axsome Therapeutics, Inc. gets broad label for new depression drug; argenx N.V. CEO on Vyvgart’s success; Chinese firms delist from US; solid results for Novo Nordisk A/S’s new diabetes combo; and women leaders herald change at foreign firms in India.

This and all our other podcasts are available on the Pharma Intelligence channel on Apple PodcastsGoogle PodcastsSoundCloudTuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.  

Stories mentioned in this episode:

(Also see "Axsome’s Wait Pays Off With Broad Auvelity Label For Major Depression" - Scrip, 19 Aug, 2022.)

(Also see "Argenx CEO Shares Secrets Of Vyvgart’s Stellar Success" - Scrip, 22 Aug, 2022.)

(Also see "Delisting Looms As More US-Listed China Companies Seek To Move Closer Home" - Scrip, 23 Aug, 2022.)

(Also see "Novo Nordisk’s New Diabetes Combo Shows Potential To Best Lilly’s Mounjaro" - Scrip, 23 Aug, 2022.)

(Also see "The Old Order Changeth: Women CEOs at Foreign Firms In India Chart New Course" - Scrip, 19 Aug, 2022.)

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC146959

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel